A post hoc analysis from the ODYSSEY OUTCOMES trial of the PCSK9 inhibitor, alirocumab, following acute coronary syndrome, has failed to show any increased risk of serious bleeding in patients with low baseline Lp(a) or reduced levels following treatment.1
